Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (809)	9/15/1998 3:48:00 PM
From: aknahow	Read Replies (2) \| Respond to of 1722

Anthony, I was just kidding about your Viagra post. The Eisinger article is great and covers all sides of the issue. At only $70 per year for daily articles of value on many aspects of the market I feel bad giving it away for free. Advise anyone to get a free trial and then spend the $70. Cancel your subscription to something else as you won't have time to read it anymore. Here is the start and conclusion. Few, if any, investors think the drug won't get the nod for rheumatoid arthritis (RA), a disease in which a patient's own immune system attacks itself, leading to debilitating pain and swelling. Enbrel is a receptor that floats freely in the body soaking up a protein called Tumor Necrosis Factor. TNF is a necessary immune system cytokine that is overproduced by RA patients. XXXXXX XXXXX XXXXX XXXX XXXX "Concludes Sacane with wise words that extend beyond the Enbrel situation: "Our philosophy remains that any time investors must rely on a biotech company to perfectly navigate its way through multiple commercialization obstacles in order to merely justify current valuation, the risk-to-reward ratio almost always favors selling the stock." Not that the copyright laws expire in a few days but I will post the entire thing by Friday. Don't own stock in any of the companies covered but just think it's an insightful article.